Bioaffinity Technologies Warrant Stock Performance
| BIAFW Stock | USD 0.60 0.03 5.26% |
The firm shows a Beta (market volatility) of -1.88, which signifies a somewhat significant risk relative to the market. As returns on the market increase, returns on owning BioAffinity Technologies are expected to decrease by larger amounts. On the other hand, during market turmoil, BioAffinity Technologies is expected to outperform it. Please check BioAffinity Technologies' potential upside, as well as the relationship between the rate of daily change and period momentum indicator , to make a quick decision on whether BioAffinity Technologies' price patterns will revert.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days bioAffinity Technologies Warrant has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly fragile technical and fundamental indicators, BioAffinity Technologies may actually be approaching a critical reversion point that can send shares even higher in December 2024. ...more
1 | Disposition of 7142 shares by Knight Peter S of BioAffinity Technologies at 4.2 subject to Rule 16b-3 | 09/13/2024 |
2 | Disposition of tradable shares by Zannes Maria of BioAffinity Technologies subject to Rule 16b-3 | 09/19/2024 |
3 | Acquisition by Steven Girgenti of 7657 shares of BioAffinity Technologies at 4.2 subject to Rule 16b-3 | 09/20/2024 |
4 | Acquisition by Diamond Stuart of 10245 shares of BioAffinity Technologies at 1.83 subject to Rule 16b-3 | 10/02/2024 |
5 | bioAffinity Technologies Announces Pricing of 2.66 Million Registered Direct Offering Concurrent Private Placement | 10/18/2024 |
6 | Acquisition by Zannes Timothy P of 3619 shares of BioAffinity Technologies subject to Rule 16b-3 | 11/14/2024 |
| Begin Period Cash Flow | 11.4 M | |
| Free Cash Flow | -6.1 M |
BioAffinity |
BioAffinity Technologies Relative Risk vs. Return Landscape
If you would invest 119.00 in bioAffinity Technologies Warrant on August 29, 2024 and sell it today you would lose (59.00) from holding bioAffinity Technologies Warrant or give up 49.58% of portfolio value over 90 days. bioAffinity Technologies Warrant is currently producing 0.1977% returns and takes up 17.1877% volatility of returns over 90 trading days. Put another way, most equities are less risky on the basis of their return distribution than BioAffinity, and majority of traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
BioAffinity Technologies Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for BioAffinity Technologies' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as bioAffinity Technologies Warrant, and traders can use it to determine the average amount a BioAffinity Technologies' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0115
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | BIAFW | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 17.19 actual daily | 96 96% of assets are less volatile |
Expected Return
| 0.2 actual daily | 3 97% of assets have higher returns |
Risk-Adjusted Return
| 0.01 actual daily | 0 Most of other assets perform better |
Based on monthly moving average BioAffinity Technologies is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of BioAffinity Technologies by adding BioAffinity Technologies to a well-diversified portfolio.
BioAffinity Technologies Fundamentals Growth
BioAffinity Stock prices reflect investors' perceptions of the future prospects and financial health of BioAffinity Technologies, and BioAffinity Technologies fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on BioAffinity Stock performance.
| Return On Equity | -1.52 | ||||
| Return On Asset | -0.7 | ||||
| Profit Margin | (1.19) % | ||||
| Operating Margin | (0.87) % | ||||
| Revenue | 2.53 M | ||||
| EBITDA | (7.63 M) | ||||
| Net Income | (7.94 M) | ||||
| Cash And Equivalents | 214.4 K | ||||
| Cash Per Share | 0.08 X | ||||
| Total Debt | 1.58 M | ||||
| Current Ratio | 0.02 X | ||||
| Book Value Per Share | 0.52 X | ||||
| Cash Flow From Operations | (6.04 M) | ||||
| Total Asset | 8.22 M | ||||
| Retained Earnings | (44.6 M) | ||||
| Working Capital | 1.72 M | ||||
About BioAffinity Technologies Performance
Evaluating BioAffinity Technologies' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if BioAffinity Technologies has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if BioAffinity Technologies has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 3.88 | 3.68 | |
| Return On Tangible Assets | (1.33) | (1.39) | |
| Return On Capital Employed | (1.33) | (1.27) | |
| Return On Assets | (0.97) | (1.01) | |
| Return On Equity | (1.63) | (1.55) |
Things to note about BioAffinity Technologies performance evaluation
Checking the ongoing alerts about BioAffinity Technologies for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for BioAffinity Technologies help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| BioAffinity Technologies had very high historical volatility over the last 90 days | |
| BioAffinity Technologies has some characteristics of a very speculative penny stock | |
| BioAffinity Technologies has a very high chance of going through financial distress in the upcoming years | |
| bioAffinity Technologies Warrant has accumulated 1.58 M in total debt. BioAffinity Technologies has a current ratio of 0.02, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Note, when we think about BioAffinity Technologies' use of debt, we should always consider it together with its cash and equity. | |
| The entity reported the revenue of 2.53 M. Net Loss for the year was (7.94 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| bioAffinity Technologies Warrant has accumulated about 214.4 K in cash with (6.04 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.08. | |
| Latest headline from businesswire.com: Acquisition by Zannes Timothy P of 3619 shares of BioAffinity Technologies subject to Rule 16b-3 |
- Analyzing BioAffinity Technologies' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether BioAffinity Technologies' stock is overvalued or undervalued compared to its peers.
- Examining BioAffinity Technologies' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating BioAffinity Technologies' management team can have a significant impact on its success or failure. Reviewing the track record and experience of BioAffinity Technologies' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of BioAffinity Technologies' stock. These opinions can provide insight into BioAffinity Technologies' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for BioAffinity Stock Analysis
When running BioAffinity Technologies' price analysis, check to measure BioAffinity Technologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioAffinity Technologies is operating at the current time. Most of BioAffinity Technologies' value examination focuses on studying past and present price action to predict the probability of BioAffinity Technologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioAffinity Technologies' price. Additionally, you may evaluate how the addition of BioAffinity Technologies to your portfolios can decrease your overall portfolio volatility.